Log in

Relevant bibliographies by topics / Propranolol / Journal articles

To see the other types of publications on this topic, follow the link: Propranolol.

Journal articles on the topic 'Propranolol'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Propranolol.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kobeleva, Tatyana A., Alik I. Sichko, Marina I. Popova, and Elena M. Shapovalova. "Development and validation of a spectrophotometric method for the analysis of propranolol in a new soft dosage form "Propranozol"." Человек и его здоровье 24, no. 4 (2021): 83–90. http://dx.doi.org/10.21626/vestnik/2021-4/11.

Full text

Abstract:

At present, the issue of creating and introducing into medical practice domestically produced drugs, the quality of man-ufacture of which is established using objective, highly sensitive optical physical and chemical methods, becomes relevant. Objective: to develop a spectrophotometric method for analysis of propranololol in the ointment "Propranozol" made on the basis of "Tizol" gel. Materials and methods. Pharmaceutical substance propranolol, gel "Tizol", soft dosage form "Propranosol" containing 0.5% of beta-adrenoblocker in titanium-containing base were used in the study. The analysis was

APA, Harvard, Vancouver, ISO, and other styles

2

Gajkiewicz, Magdalena, Radosław Zaucha, Julia Silldorff, et al. "Propranolol in treating various symptoms associated with autism spectrum disorder (ASD)." Quality in Sport 19 (August 17, 2024): 53778. http://dx.doi.org/10.12775/qs.2024.19.53778.

Full text

Abstract:

Introduction and purpose This review provides an in-depth exploration of the pharmacology of propranolol, elucidating its mechanisms of action and clinical implications beyond its conventional indications, contextualizing propranolol’s role in ASD management. State of knowledge Propranolol is a non-cardioselective β-adrenergic receptor antagonist, commonly used among the population. Propranolol's mechanisms include reducing cardiac workload, vasoconstriction, and membrane stabilizing properties, which suggest its utility in managing anxiety. ASD, characterized by deficits in social interaction

APA, Harvard, Vancouver, ISO, and other styles

3

Li, Mi, and Yanqin Ji. "Propranolol Inhibits the Growth of Cervical Cancer Cells by Inhibiting Cyclic Guanosine Monophosphate/Protein Kinase G (cGMP/PKG) Pathway." Journal of Biomaterials and Tissue Engineering 12, no. 2 (2022): 422–26. http://dx.doi.org/10.1166/jbt.2022.2916.

Full text

Abstract:

This study assesses the therapeutic effect of propranolol on cervical cancer and its mechanism. Propranolol’s effect on cervical cancer was evaluated by MTT, Western blotting, flow cytometry and colony formation. By searching Drug Bank and String, cGMP/PKG signaling might be downstream targets of propranolol for subsequent analysis. Our results found that propranolol could significantly inhibit Hela and SiHA cell vitality and clone formation in a dose dependent manner. Further, Annexin V-PE/7-AAD Apoptosis Detection assay showed that propranolol could increase Hela and SiHA cell apoptosis. Fin

APA, Harvard, Vancouver, ISO, and other styles

4

Sowinski, Kevin M., and Brad S. Burlew. "Impact of CYP2D6 Poor Metabolizer Phenotype on Propranolol Pharmacokinetics and Response." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17, no. 6 (1997): 1305–10. http://dx.doi.org/10.1002/j.1875-9114.1997.tb03097.x.

Full text

Abstract:

We conducted an open‐label study to determine the impact of cytochrome P‐4502D6 (CYP2D6) on propranolol pharmacokinetics and response in 12 healthy men with CYP2D6 extensive metabolizer (EM) phenotype and 3 healthy men with CYP2D6 poor metabolizer (PM) phenotype. Subjects received R,S‐propranolol hydrochloride 80 mg every 8 hours for 16 doses. After the sixteenth dose, blood and urine samples were collected for 24 hours, and serum propranolol and urine metabolite concentrations were determined by chiral high‐performance liquid chromatography. Heart rate response to treadmill exercise was measu

APA, Harvard, Vancouver, ISO, and other styles

5

Hurley, Elisa A. "Pharmacotherapy to Blunt Memories of Sexual Violence: What's a Feminist to Think?" Hypatia 25, no. 3 (2010): 527–52. http://dx.doi.org/10.1111/j.1527-2001.2010.01108.x.

Full text

Abstract:

It has recently been discovered that propranolol—a beta-blocker traditionally used to treat cardiac arrhythmias and hypertension—might disrupt the formation of the emotionally disturbing memories that typically occur in the wake of traumatic events and consequently prevent the onset of trauma-induced psychological injuries such as Post-traumatic Stress Disorder. One context in which the use of propranolol is generating interest in both the popular and scientific press is sexual violence. Nevertheless, feminists have so far not weighed in on propranolol. I suggest that the time is ripe for a ca

APA, Harvard, Vancouver, ISO, and other styles

6

Alotaibi, Hadil Faris, Haifa Alotaibi, Khaled M. Darwish, et al. "The Anti-Virulence Activities of the Antihypertensive Drug Propranolol in Light of Its Anti-Quorum Sensing Effects against Pseudomonas aeruginosa and Serratia marcescens." Biomedicines 11, no. 12 (2023): 3161. http://dx.doi.org/10.3390/biomedicines11123161.

Full text

Abstract:

The development of bacterial resistance is an increasing global concern that requires discovering new antibacterial agents and strategies. Bacterial quorum sensing (QS) systems play important roles in controlling bacterial virulence, and their targeting could lead to diminishing bacterial pathogenesis. In this context, targeting QS systems without significant influence on bacterial growth is assumed as a promising strategy to overcome resistance development. This study aimed at evaluating the anti-QS and anti-virulence activities of the β-adrenoreceptor antagonist propranolol at sub-minimal in

APA, Harvard, Vancouver, ISO, and other styles

7

Kumar, Lalit, and Puneet Utreja. "Oleic Acid Vesicles for Transdermal Delivery of Propranolol Hydrochloride: Development and Characterization." Current Drug Therapy 15, no. 3 (2020): 238–48. http://dx.doi.org/10.2174/1574885514666190722164119.

Full text

Abstract:

Background: Pharmaceutical scientists are exploring transdermal route for treatment of various systemic diseases nowadays. Transdermal nanocarrier systems show various advantages like bioavailability enhancement of drugs, avoidance of first pass hepatic metabolism, and reduction of dosing frequency of bioactive therapeutic molecules. Objective: The objective of the present research work was to encapsulate Propranolol hydrochloride into oleic acid vesicles and carry out in-vitro and in-vivo evaluation of oleic acid vesicular gel containing Propranolol hydrochloride. Method: Propranol hydrochlor

APA, Harvard, Vancouver, ISO, and other styles

8

Miguel-Puga, Adán, Gabriel Villafuerte, Mario Treviño, Emmanuel Ortega-Robles, and Oscar Arias-Carrión. "Effect of Propranolol on Motor Cortex Excitability in Essential Tremor: An Exploratory Study." Tremor and Other Hyperkinetic Movements 14 (January 2, 2024): 1. http://dx.doi.org/10.5334/tohm.829.

Full text

Abstract:

Background: Essential tremor, the world’s most prevalent movement disorder, lacks a clear understanding of its pathophysiology. Propranolol, a non-specific beta-blocker capable of crossing the blood-brain barrier, is a primary choice for essential tremor treatment. While its tremor-reducing effects are generally attributed to peripheral actions, various uses hint at central adrenergic effects. Nevertheless, propranolol’s precise impact on the central nervous system in essential tremor subjects remains unexplored. Methods: In this study, we employed transcranial magnetic stimulation to assess t

APA, Harvard, Vancouver, ISO, and other styles

9

Gulzar, G. M., Showkat A. Zargar, M. S. Alai, et al. "Effect of acute administration of propranolol, carvedilol, iso-sorbide dinitrate, “propranolol plus iso-sorbide dinitrate” and “carvedilol plus iso-sorbide dinitrate” on portal venus pressure." JMS SKIMS 16, no. 2 (2013): 80–85. http://dx.doi.org/10.33883/jms.v16i2.215.

Full text

Abstract:

Pharmacotherapy of portal hypertension in patients with cirrhosis includes beta-blockers, nitrates, somatastain analogues, alpha-blockers like prazocin. These drugs differ widely in their effectiveness, adverse effects and patient compliance. Beta-blockers particularly propranolol are the most commonly used drugs. Of late, carvedilol has been used and found to be superior to propranolol. The present study was aimed at assessing the effect of propranolol, carvedilol, iso-sorbide dinitrate; combination of “propranolol and iso-sorbide-dinitrate” and carvedilol and isosorbide dinitrate” on portal

APA, Harvard, Vancouver, ISO, and other styles

10

Rešić, Arnes, Zdenka Pleša Premilovac, Filip Jurić, and Marko Mesić. "Hipoglikemija – nuspojava terapije propranololom dojenačkih hemangioma – prikaz triju slučajeva." Paediatria Croatica 58, no. 4 (2014): 310–14. http://dx.doi.org/10.13112/pc.605.

Full text

Abstract:

Peroralno primijenjen propranolol u dozi od 1-3 mg/kg/dan terapija je izbora kompliciranih hemangioma dojenačke dobi. Prikazujemo dva bolesnika s nastankom simptomatske hipoglikemije i jednog bolesnika s nastankom konvulzija najvjerojatnije povezanihs hipoglikemijom, koji su na peroralnoj terapiji propranololom radi liječenja dojenačkih hemangioma. Iako se propranolol priličnodugo primjenjuje u drugim indikacijama, i čini se pouzdanim lijekom, baš zbog svoje neselektivnosti u djelovanju potrebno je prepoznati moguće i rjeđe nuspojave kao što je hipoglikemija, posebice u novim indikacijama za p

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Propranolol see Maprotiline/propranolol." Reactions Weekly &NA;, no. 341 (1991): 10. http://dx.doi.org/10.2165/00128415-199103410-00057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lucido, Christopher, W. Miskimins, and Paola Vermeer. "Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC." Cancers 10, no. 12 (2018): 476. http://dx.doi.org/10.3390/cancers10120476.

Full text

Abstract:

Tumor cell metabolism differs from that of normal cells, conferring tumors with metabolic advantages but affording opportunities for therapeutic intervention. Accordingly, metabolism-targeting therapies have shown promise. However, drugs targeting singular metabolic pathways display limited efficacy, in part due to the tumor’s ability to compensate by using other metabolic pathways to meet energy and growth demands. Thus, it is critical to identify novel combinations of metabolism-targeting drugs to improve therapeutic efficacy in the face of compensatory cellular response mechanisms. Our lab

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Propranolol see Butalbital/imipramine/propranolol." Reactions Weekly &NA;, no. 381 (1991): 10. http://dx.doi.org/10.2165/00128415-199103810-00050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Propranolol see Captopril/methyldopa/propranolol." Reactions Weekly &NA;, no. 305 (1990): 7. http://dx.doi.org/10.2165/00128415-199003050-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Tchivileva, Inna E., Richard Ohrbach, Roger B. Fillingim, et al. "Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial." Cephalalgia 41, no. 7 (2021): 839–50. http://dx.doi.org/10.1177/0333102421989268.

Full text

Abstract:

Introduction The migraine-preventive drug propranolol is efficacious in reducing pain from temporomandibular disorder, suggesting potential modifying or mediating effects of comorbid migraine. Methods In this randomized controlled trial, myofascial temporomandibular disorder patients were treated with propranolol or placebo for 9 weeks. The primary endpoint was change in a facial pain index derived from daily symptom diaries. Linear and logistic regression models tested for a migraine × treatment-group interaction in reducing facial pain index. Counterfactual models explored changes in headach

APA, Harvard, Vancouver, ISO, and other styles

16

Welle, S. L., K. S. Nair, and R. G. Campbell. "Failure of chronic beta-adrenergic blockade to inhibit overfeeding-induced thermogenesis in humans." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 256, no. 3 (1989): R653—R658. http://dx.doi.org/10.1152/ajpregu.1989.256.3.r653.

Full text

Abstract:

The effect of the beta-adrenergic antagonist propranolol on the increase in resting metabolic rate (RMR) induced by overfeeding was examined to determine whether increased beta-adrenergic activity contributes to this response. Six male subjects who were overfed with carbohydrate (1,600 excess kcal/day) for 10 days without drug treatment (control group) had increases (compared with values after 10 days of weight maintenance) in RMR after 6 days [0.24 +/- 0.06 kcal/min (22%)] and 10 days of overfeeding [0.17 +/- 0.03 kcal/min (15%)]. Eight male subjects were given a weight-maintenance diet for 1

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1377 (2011): 32–33. http://dx.doi.org/10.2165/00128415-201113770-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1384 (2012): 48. http://dx.doi.org/10.2165/00128415-201213840-00190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1389 (2012): 36–37. http://dx.doi.org/10.2165/00128415-201213890-00132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Propranolol." Reactions Weekly &NA;, no. 759 (1999): 10. http://dx.doi.org/10.2165/00128415-199907590-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1171 (2007): 23. http://dx.doi.org/10.2165/00128415-200711710-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1121 (2006): 20–21. http://dx.doi.org/10.2165/00128415-200611210-00065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1356 (2011): 31. http://dx.doi.org/10.2165/00128415-201113560-00106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 34. http://dx.doi.org/10.2165/00128415-201113630-00136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 35. http://dx.doi.org/10.2165/00128415-201113630-00137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 35. http://dx.doi.org/10.2165/00128415-201113630-00140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1363 (2011): 35. http://dx.doi.org/10.2165/00128415-201113630-00141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1364 (2011): 38. http://dx.doi.org/10.2165/00128415-201113640-00148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1366 (2011): 25–26. http://dx.doi.org/10.2165/00128415-201113660-00094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1367 (2011): 32. http://dx.doi.org/10.2165/00128415-201113670-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Propranolol." Reactions Weekly &NA;, no. 562 (1995): 10. http://dx.doi.org/10.2165/00128415-199505620-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Propranolol." Reactions Weekly &NA;, no. 428 (1992): 11. http://dx.doi.org/10.2165/00128415-199204280-00053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Propranolol." Reactions Weekly &NA;, no. 432 (1992): 15. http://dx.doi.org/10.2165/00128415-199204320-00083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Propranolol." Reactions Weekly &NA;, no. 457 (1993): 12. http://dx.doi.org/10.2165/00128415-199304570-00048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Propranolol." Reactions Weekly &NA;, no. 458 (1993): 10. http://dx.doi.org/10.2165/00128415-199304580-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Propranolol." Reactions Weekly &NA;, no. 683 (1998): 11–12. http://dx.doi.org/10.2165/00128415-199806830-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1400 (2012): 35. http://dx.doi.org/10.2165/00128415-201214000-00133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1402 (2012): 38–39. http://dx.doi.org/10.2165/00128415-201214020-00142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1408 (2012): 27. http://dx.doi.org/10.2165/00128415-201214080-00094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1409 (2012): 38. http://dx.doi.org/10.2165/00128415-201214090-00125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1415 (2012): 41–42. http://dx.doi.org/10.2165/00128415-201214150-00149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1415 (2012): 42. http://dx.doi.org/10.2165/00128415-201214150-00151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1416 (2012): 37. http://dx.doi.org/10.2165/00128415-201214160-00122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Propranolol." Reactions Weekly &NA;, no. 372 (1991): 8. http://dx.doi.org/10.2165/00128415-199103720-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Propranolol." Reactions Weekly &NA;, no. 403 (1992): 7. http://dx.doi.org/10.2165/00128415-199204030-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Propranolol." Reactions Weekly &NA;, no. 417 (1992): 10. http://dx.doi.org/10.2165/00128415-199204170-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1111 (2006): 19. http://dx.doi.org/10.2165/00128415-200611110-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1114 (2006): 16–17. http://dx.doi.org/10.2165/00128415-200611140-00047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Propranolol." Reactions Weekly &NA;, no. 924 (2002): 10. http://dx.doi.org/10.2165/00128415-200209240-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Propranolol." Reactions Weekly &NA;, no. 1280 (2009): 39. http://dx.doi.org/10.2165/00128415-200912800-00133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!